The latest delayed quote for Vertex Pharmaceuticals Incorporated (VRTX) stock was $546.12 as of Sep 4, 2026, 4:00 PM EDT, down 2.12% from the previous close.
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene.
